陈云

师资介绍

陈云，女，汉族，1987年10月生，博士，讲师，硕士生导师。

教育经历：

2006.09-2011.06山东第一医科大学，药学（临床药学方向），学士

2011.09-2014.06南通大学，药理学，硕士

2017.06-2020.06南通大学，基础医学，博士

2022.09-2022.12澳门科技大学，访问学者

工作经历：

2014.08-2017.09江苏省南通卫生高等职业技术学校，药理学，助教

2020.10-至今 南通大学，药学院，讲师

研究方向：

心血管药理学

社会学术兼职：

江苏省药理学会临床前药理专业委员会委员。

基金项目：

1. 江苏省高等学校基础科学(自然科学)面上项目, 21KJB310014, TRADD调控心肌缺血 再灌注损伤中坏死性凋亡的作用及机制研究, 2021-10至2023-09, 3万元,在研,主持

2. 国家自然科学基金委员会,青年科学基金项目, 82200313, XBP1介导TRADD转录进而调控焦亡在糖尿病 心肌病中的作用及机制研究, 2023-01-01至2025-12-31, 30万元,在研,主持

3. 国家自然科学基金委员会,面上项目, 82270418,视黄酸相关孤核受体α在糖尿病血管内皮功能障碍 中的作用及机制研究, 2023-01-01至2026-12-31, 52万元,在研,参与

4. 国家自然科学基金委员会,面上项目, 81972815, LncRNA LINC01940协同CEBPB介导超级增强子HDAC4- SE转录激活TWIST2促进肺腺癌化疗耐药的机制研究, 2020-01-01至2023-12-31, 55万元,资助期满,参与

5. 国家自然科学基金委员会,面上项目, 81970226, SUMO化修饰调节RhoGDI蛋白降解在AngІІ介导的VSMC表型转化和动脉血管重构中的作用及机制研究, 2020-01-01至2023-12-31, 55万元,资助期满,参与

科研成果：

近年来从事心血管疾病基础研究，主要对心肌缺血再灌注、心肌肥厚、糖尿病心肌病等疾病发病机制做了系列研究，目前已作为第一作者/并列第一作者或通讯作者等在Acta Pharmacologica Sinica、Biomedicine&Pharmacotherapy、Frontiers in Pharmacology、Biochemical Pharmacology、International Journal of Molecular Sciences等相关期刊发表SCI论文10余篇。

代表性论文：

1. Yangyang Zheng, Yongji Xu, Li Ji, Wenqing San, Danning Shen, Qianyou Zhou, Guoliang Meng, Jiahai Shi, Yun Chen*. Roles of distinct nuclear receptors in diabetic cardiomyopathy. Front Pharmacol. 2024:15:1423124.

2. Linlin Sun, Yujiao Xiao, Wenqing San, Yun Chen*, Guoliang Meng. Dihydromyricetin regulates RIPK3-CaMKII to prevent necroptosis in high glucose-stimulated cardiomyocytes. Heliyon. 2024 Mar 29;10(7):e28921.

3. Jieru Shen, Wenqing San, Yangyang Zheng, Shuping Zhang, Danyi Cao,Yun Chen, Guoliang Meng. Different types of cell death in diabetic endothelial dysfunction, Biomedicine & Pharmacotherapy, 2023, 168: 115802.

4. Yun Chen, Shu-Ping Zhang, Wei-Wei Gong, Yang-Yang Zheng, Jie-Ru Shen, Xiao Liu, Yun-Hui Gu, Jia-Hai Shi, Guo-Liang Meng. Novel Therapeutic Potential of Retinoid-Related Orphan Receptor α in Cardiovascular Diseases, International Journal of Molecular Sciences, 2023, 24(4):3462

5. Yun Chen, Yangyang Zheng, Ruixiang Chen, Jieru Shen, Shuping Zhang, Yunhui Gu, Jiahai Shi, Guoliang Meng. Dihydromyricetin Attenuates Diabetic Cardiomyopathy by Inhibiting Oxidative Stress, Inflammation and Necroptosis via Sirtuin 3 Activation, Antioxidants, 2023, 12(1): 200- 200

6. Shuping Zhang, Jieru Shen, Yu Zhu, Yangyang Zheng, Wenqing San, Danyi Cao,Yun Chen*, Guoliang Meng. Hydrogen sulfide promoted retinoic acid-related orphan receptorα transcription to alleviate diabetic cardiomyopathy, Biochemical Pharmacology, 2023, 215: 115748

7. Yun Chen, Yunhui Gu, Xing Xiong, Yangyang Zheng, Xiao Liu, Weiqi Wang, Guoliang Meng. Roles of the adaptor protein tumor necrosis factor receptor type 1-associated death domain protein (TRADD) in human diseases., Biomedicine & Pharmacotherapy, 2022, 153: 113467-113467.

8. Yun Chen, Xinshuai Li, Yuyun Hua, Yue Ding, Guoliang Meng , Wei Zhang. RIPK3-Mediated Necroptosis in Diabetic Cardiomyopathy Requires CaMKII Activation. Oxid Med Cell Longev. 2021 Jun 7:2021:6617816.

9. Yun Chen, Yuyun Hua, Xinshuai Li, Ishfaq Muhammad Arslan, Wei Zhang, Guoliang Meng. Distinct Types of Cell Death and the Implication in Diabetic Cardiomyopathy. Front Pharmacol. 2020:11:42.

10. Yu-Yun Hua, Yue Zhang, Wei-Wei Gong, Yue Ding, Jie-Ru Shen, Hua Li, Yun Chen*, Guo-Liang Meng. Dihydromyricetin Improves Endothelial Dysfunction in Diabetic Mice via Oxidative Stress Inhibition in a SIRT3-Dependent Manner. Int J Mol Sci. 2020;21(18):6699.

11. YunChen, Hui-Qin Luo, Lin-Lin Sun, Meng-Ting Xu, Jin Yu, Lu-Lu Liu, Jing-Yao Zhang, Yu-Qin Wang, Hong-Xia Wang, Xiao-Feng Bao, Guo-Liang Meng. Dihydromyricetin Attenuates Myocardial Hypertrophy Induced by Transverse Aortic Constriction via Oxidative Stress Inhibition and SIRT3 Pathway Enhancement. Int J Mol Sci. 2018;19(9):2592.